Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Melanoma 1Liver Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 4Cyclophosphamide 4fludarabine 3Nivolumab 3Ipilimumab 3Drug Therapy 3aldesleukin 2Biopsy 2utomilumab 1trastuzumab deruxtecan 1sargramostim 1poly ICLC 1liposomal doxorubicin 1fludarabine phosphate 1erythromycin propionate-N-acetylcysteinate 1enzalutamide 1durvalumab 1brodalumab 1atezolizumab 1advexin 1Sirolimus 1Radiotherapy, Conformal 1Quality of Life 1Psychology, Positive 1Poly I-C 1Patient Reported Outcome Measures 1Observation 1National Cancer Institute (U.S.) 1Molecular Diagnostic Techniques 1Microscopy, Electron 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × C188-9 compound × Dermatologic × Clear all
NCT03195699 2025-03-21

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Tvardi Therapeutics, Incorporated

Phase 1 Completed
64 enrolled
BreastDermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡